NYSE:PRGOPharmaceuticals
Why Perrigo (PRGO) Is Down 22.0% After Deepening 2025 Losses And Weaker 2026 Sales Guidance
Perrigo Company plc recently reported full-year 2025 results showing sales of US$4,253.1 million, with net loss widening to US$1,425.4 million, and also issued 2026 guidance pointing to a further 1.5%–5.5% decline in total net sales versus the prior year.
Despite this much larger loss, including a particularly weak fourth quarter, the board maintained its quarterly dividend at US$0.29 per share, signaling a continued cash return to shareholders.
We’ll now examine how Perrigo’s sharply higher...